Literature DB >> 1717130

A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.

G J Peters1, C J van Groeningen, E J Laurensse, H M Pinedo.   

Abstract

The metabolism of 5-fluorouracil (5-FU) was studied in biopsy specimens of primary colorectal cancer and healthy colonic mucosa obtained from previously untreated patients immediately after surgical removal. The conversion of 5-FU to anabolites was measured under saturating substrate (5-FU) and cosubstrate concentrations. For all enzymes, the activity was about threefold higher in tumor tissue compared with healthy mucosa of the same patient. The activity of pyrimidine nucleoside phosphorylase with deoxyribose-1-phosphate (dRib-1-P) was about tenfold higher (about 130 and 1200 nmol/hr/mg protein in tumors) than with ribose-1-phosphate (Rib-1-P), both in tumor and mucosa. Synthesis of the active nucleotides (5-fluoro-uridine-5'-monophosphate [FUMP] and 5-fluoro-2'-deoxyuridine-5'-monophosphate [FdUMP]) was studied by adding physiologic concentrations of adenosine triphosphate (ATP) to the reaction mixture; the rate of FdUMP synthesis was 50% of that of FUMP (about 4 and 7 nmol/hr/mg protein in tumors). Direct synthesis of FUMP from 5-FU in the presence of 5-phosphoribosyl-1-pyrophosphate (PRPP) was about 2 nmol/hr/mg protein. With the natural substrate for this reaction, orotic acid, the activity was about 14-fold higher. To obtain insight into the recruitment of precursors for these cosubstrates, the authors also tested the enzyme activity of pyrimidine nucleoside phosphorylase with inosine and ribose-5-phosphate (Rib-5-P, as precursors for Rib-1-P) and deoxyinosine (as a precursor for dRib-1-P); enzyme activities were approximately 7%, 7%, and 3%, respectively, of that with the normal substrates, both in tumors and mucosa. However, when ATP and Rib-5-P were combined, the synthesis of FUMP was about 70% of that with PRPP, but only in tumors. In normal tissues no activity was detectable. These data suggest a preference of colon tumor over colon mucosa for the conversion of 5-FU to active nucleotides by a direct pathway; a selective antitumor effect of 5-FU may be related to this difference.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717130     DOI: 10.1002/1097-0142(19911101)68:9<1903::aid-cncr2820680910>3.0.co;2-9

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors.

Authors:  Akira Yano; Yoshinori Shigematsu; Hiroyuki Kitano; Aki Hanayama; Akira Ozawa; Takatoshi Tacho; Motohiro Fujii
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

Review 2.  Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway.

Authors:  Wataru Ichikawa
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

Review 3.  Clinical pharmacokinetics of capecitabine.

Authors:  B Reigner; K Blesch; E Weidekamm
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  A 10-year survivor with unresectable hepatic metastases from sigmoid colon carcinoma treated with regional chemotherapy.

Authors:  S Takeda; K Hisatomi; S Nakano; K Okamoto; Y Nagafuchi; H Itoh; K Ohsato
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Biochemical modulation of 5-fluorouracil with or without leucovorin by a low dose of brequinar in MGH-U1 cells.

Authors:  T L Chen; C Erlichman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer.

Authors:  Hidehiro Tajima; Tetsuo Ohta; Hirohisa Kitagawa; Koichi Okamoto; Seisho Sakai; Isamu Makino; Jun Kinoshita; Hiroyuki Furukawa; Keishi Nakamura; Hironori Hayashi; Katsunobu Oyama; Masafumi Inokuchi; Hisatoshi Nakagawara; Hideto Fujita; Hiroyuki Takamura; Itasu Ninomiya; Sachio Fushida; Takashi Tani; Takashi Fujimura; Hiroko Ikeda; Seiko Kitamura
Journal:  Exp Ther Med       Date:  2012-02-13       Impact factor: 2.447

7.  Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil.

Authors:  Chariya Hahnvajanawong; Jariya Chaiyagool; Wunchana Seubwai; Vajarabhongsa Bhudhisawasdi; Nisana Namwat; Narong Khuntikeo; Banchob Sripa; Ake Pugkhem; Wichittra Tassaneeyakul
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

8.  Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.

Authors:  Yoichi Sakurai; Shingo Kamoshida; Shinpei Furuta; Risaburo Sunagawa; Kazuki Inaba; Jun Isogaki; Yoshiyuki Komori; Ichiro Uyama; Yutaka Tsutsumi
Journal:  Gastric Cancer       Date:  2007-12-25       Impact factor: 7.370

9.  Prolonged retention of high concentrations of 5-fluorouracil in human and murine tumors as compared with plasma.

Authors:  G J Peters; J Lankelma; R M Kok; P Noordhuis; C J van Groeningen; C L van der Wilt; S Meyer; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

10.  Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.

Authors:  Liyi Geng; Amelia M Huehls; Jill M Wagner; Catherine J Huntoon; Larry M Karnitz
Journal:  PLoS One       Date:  2011-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.